Citation:Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al 2004

Citation

Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004 May 15;59(3):311-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15042607.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al 2004	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Tracy Tsang	completed
Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al 2004 2	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Suzanne Hughes	completed

Compare quality appraisals for each clinical question

• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)

Cited by

1. Discussion
2. PSA Testing strategies